Shopping Cart
- Remove All
- Your shopping cart is currently empty
PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $97 | In Stock | |
10 mg | $161 | In Stock | |
25 mg | $324 | In Stock | |
50 mg | $537 | In Stock | |
100 mg | $649 | In Stock | |
500 mg | $1,380 | In Stock | |
1 mL x 10 mM (in DMSO) | $86 | In Stock |
Description | PLX5622 is a highly selective, brain-penetrant, and orally active CSF1R inhibitor. |
Targets&IC50 | CSF1R:0.016 µM (IC50), CSF1R:Ki: 5.9 nM |
In vitro | METHODS: CX CR1+/GFP mouse-derived mixed glial cell cultures were treated with PLX5622 (0.1-10 µM) for 7 days and cell counts were assayed by Flow cytometry. RESULTS: Although there was a dose-dependent decrease in microglia numbers under PLX5622, no decrease in GFAP+ astrocytes was seen, but rather a gradual increase, along with a decrease in PDGFR-a OPC. [1] METHODS: Cerebellar sections prepared from PLP-eGFP mouse pups were treated with PLX5622 (1-20 µM) for 3 days followed by Immunostaining. RESULTS: After three days of treatment, PLX5622 at concentrations greater than 2 µM eliminated more than 95% of microglia. [2] |
In vivo | METHODS: To study in vivo activity, PLX5622 (1200 mg/kg) was administered to PLP eGFP mice by feed for 7-21 days. RESULTS: PLX5622 was effective in depleting microglia in the central nervous system of adult mice. treatment with PLX5622 for 7 days had no effect on oligodendrocyte progenitor cell populations; however, a mild reduction was observed after 21 days in some central nervous system regions. [2] |
Alias | PLX-5622 |
Molecular Weight | 395.41 |
Formula | C21H19F2N5O |
Cas No. | 1303420-67-8 |
Smiles | COc1ncc(F)cc1CNc1ccc(Cc2c[nH]c3ncc(C)cc23)c(F)n1 |
Relative Density. | 1.364 g/cm3 (Predicted) |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
Solubility Information | DMSO: 16.67 mg/mL (42.15 mM), Sonication is recommended. ![]() | |||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 7.9 mg/mL (19.98 mM), suspension.In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.